The FLOW trial has recently provided clear evidence for kidney protection with semaglutide
So, whether you're a person with a high, a hypo, low functioning thyroid, or you're a person who's got Cushing's when we look at the obese population, 10% of them 9 to 10% of the research actually have Cushing's
The PlexusDx Precision Peptide Genetic Test identifies these peptide-pathway variants, revealing whether you may experience faster or slower medication activation
In some cases, GLP-1 therapy can be phased out once these healthy habits are well-established and effective
We can basically see hyper filtration of the kidney slowing down and then also we dont see that much protein in the urine
The main trade-offs are hidden pricing for non-core meds and a cancellation process that could be clearer